________________________________________________________________________________________________________________________________

(C) Wolf G Kroner 2010 - Jonathan BarnsleyWe have biosimilars coming …

June 2010. With more challenges ahead to face the lower cost environment of medical health care, at issue is process development to ensure peak process performance, selecting alternative technology platforms and adapting them to industrial scale. In the exclusive interview with B2Bioworld Jonathan Barnsley, Senior Vice President, Biotech Manufacturing and Process Development Merck Serono, describes opportunities and threats.

 

* Editor's Note: Mr. Barnsley left Merck in April 2014 for Ipsen Ldt. at Slough (UK) where he is responsible for technical operations

If you like to read this article, you can purchase it now

Please notice, when purchasing articles you agree to B2Bioworld's Terms and Conditions

Read Now - Please select your license (Prices incl. 7% VAT)

Article free of advertisement - 3 pages
- Includes Merck Serono Pipeline April 2010, Overview Technical and Manufacturing Operations Worldwide

Full Company License enquire here

Back to section

Related Editorial Articles

Merck: Getting closer to biosimilars markets in Asia and Latin America

Make or Break Drug Discovery and Biopharma of Merck Life Science
Andrew Bulpin, currently Global Head of Merck Millipore Process Solutions on strategy and the road ahead. Includes competitive rank of Merck Life Science Division

Eurofins: Sustainable profitability – albeit not for investors in a hurry

Custom Sequencing Markets
Worldwide evolution of the market and upcoming business opportunities

Merck Serono on stem cell research: Clear away complete confusion of terms
Bernhard Kirschbaum, today Head of Global Research and Early Development for Merck Serono on stem cell research

Drug Testing with Embryonic Stem Cells
- Towards standards of assays

Pfizer Regenerative Medicine (Neusentis): It really started last year…
Ruth McKernan, global CSO of Pfizer’s Regenerative Medicine Unit (today Neusentis) addresses basic and practical issues in pharmaceutical research on stem cells

Sanofi: Triggering Regenerative Functions with Transplanted Cells and Small Molecules
Kurt Stoeckli, Global Head of Biological Sciences / Discovery Sanofi Aventis and Scientific Director of the research site at Vitry-Alfortville

Boehringer Ingelheim: We are obliged to more and more move away from animals
Andreas Barner, Chairman of the Board of Managing Directors of Boehringer Ingelheim and Head of Corporate Board Division Pharma Research Corporate, evaluates prospects for stem technologies